HomeFocus → DEA Reschedules Epidiolex, Paving the Way to Market

DEA Reschedules Epidiolex, Paving the Way to Market Print E-mail
Written by FHI's Week in Review   
Monday, 01 October 2018 00:00
Megan Brooks reports for Medscape on 9.27.18:
The U.S. Drug Enforcement Administration (DEA) has rescheduled the epilepsy cannabidiol (CBD) drug Epidiolex (GW Pharmaceuticals) from Schedule I to Schedule V, the classification with the lowest degree of restriction - paving the way to market for the cannabis-based treatment, the company has announced. As reported by Medscape Medical News, the U.S. Food and Drug Administration (FDA) approved the drug in June for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients aged 2 years and older. The approval followed a unanimous thumbs up by an FDA advisory committee in April.
Read more in the current issue of Week in Review>>
Last Updated on Monday, 01 October 2018 17:50

Website design, development, and hosting provided by